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Introduction
Uveitis is one of the most serious manifestations of
Juvenile Idiopathic Arthritis (JIA), with the potential to
cause severe sight-threatening ocular complications. The
first line treatment consists of topical and oral steroids
with DMARDs therapy for more severe cases, including
immunosuppressive and anti-TNFa agents. Abatacept
(CTLA-4 immunoglobulin) is a soluble, fully human
fusion protein that consists of the extracellular domain
of CTLA-4, linked to a modified Fc portion of the
human immunoglobulin IgG1, which does not activate
the complement. The drug is approved for the treat-
ment of polyarticular JIA.
Objectives
We evaluated the efficacy and safety of Abatacept in a
series of young patients with sight-threatening JIA-
related and idiopathic uveitis refractory to previous anti-
TNFa agents.
Methods
We performed a monocenter collection of data of 12
patients affected by uveitis (10 JIA-related and 2 idio-
pathic) which resulted refractory to both classic immu-
nosuppressive and anti-TNFa treatments and who
started a therapy with Abatacept at a monthly dosage of
10 mg/kg, administered intravenously. Abatacept was
administered as off-label use in 7/12 patients (4 with oli-
goarticular JIA, 1 with enthesitis-related arthritis JIA and
2 with idiopathic uveitis). Nine patients reached a 6
months observation period, while the other three have
been followed for only 2 months. Side effects, mean fre-
quency of uveitis flares and ocular complications before
and after treatment were recorded.
Results
Abatacept treatment led to sustained improvement of
ocular manifestations in all patients. Results after the 6
months observation period showed a decrease in the
mean frequency of uveitis flares, which decreased from
1.66 to 0.55 (-64.75%) during the 6 months before and 6
months after treatment. In those patients who have still
not reached the 6 months observation period the
administration of Abatacept led to a severe reduction of
the mean frequency of uveitis which passed from 3.33
episodes during the two months before the administra-
tion to 0.33 after Abatacept introduction. No adverse
effects were observed. No new ocular complications or
worsening of preexisting ones were reported.
Conclusion
Our experience with Abatacept resulted positive in
terms of safety and efficacy. The introduction of Abata-
cept led to severe improvement of ocular manifestations
in both refractory JIA-related and idiopathic uveitis. Our
results confirm those of the current literature and pos-
tulate the role of Abatacept as a promising alternative
treatment in refractory uveitis.
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